



News Announcement from Incubate Bio

ALaSCAdb: Incubate Bio open sources characterized targets database for drug sensitivity and target discovery in Ovarian cancer

- *Starting with DDR pathways and PARP inhibitors, growing to cover Ovarian cancer*
- *Including in silico simulation results of the causal mechanisms*
- *Generated by our ALaSCA Cancer Model System using novel CausalAI algorithms and public datasets*

London, July 19, 2023 - Incubate Bio announces the release of its ALaSCAdb open source database for Ovarian cancer. ALaSCAdb has been developed specifically to enable rapid investigation and in silico experimentation to assist discovery and development of novel cancer therapies.

ALaSCAdb has been generated by the ALaSCA Cancer Model System, which is underpinned by a unique combination of a Large Language Model approach coupled with a powerful proven Causal AI engine. Together these allow ALaSCA to enable early-stage drug discovery groups to rapidly interrogate and extract meaningful biological insights from multiple public research literature and comprehensive datasets, and then perform causal AI on the derived mechanisms. The resulting output provides a unique Cancer Model System which can be used by scientists to find directly actionable insights for their drug discovery program.

“Accelerating target discovery and validation is critical to democratizing the drug discovery industry,” said **Professor Tony Sedgwick, Senior Industry Advisor**. *“Finding the right characterized targets is a hot topic in the industry today, and ALaSCAdb is what research and development scientists need to accelerate their target discovery work in Ovarian (and other) cancer.”*

Access to ALaSCAdb is available on request at <https://www.incubate.bio/alascadb>.

Access to the ALaSCA Cancer Model System will be initially available to drug discovery groups as a service provided by Incubate Bio’s in-house consulting team.

Dr Raminderpal Singh, CEO of Incubate Bio, will present the Cancer Model System at the London Bioinformatics meeting on July 27, and at the Google NEXT 2023 conference on August 29 in San Francisco.

+++ END +++

About Incubate Bio

For more about Incubate Bio:

<https://www.incubate.bio/>

Media Contact:

Dr Lynne Trowbridge

Bridgemoore

+44 7801 109770

info@bridgemoore.co.uk

For Incubate Bio:

Dr Raminderpal Singh, CEO

raminderpal@incubate.bio

+44 7719 622303

<https://www.incubate.bio/>